Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | December 31, 2020 | January 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date December 31, 2020 · Filed January 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,251 |
Reported balance
After 2020-12-31 transaction · row 1
1 source rowRow 1 · 2020-12-31 · Grant · Acquired 208 · Balance 49,251 F1: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Jan 4, 2021 18:36 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 208 | $15.00 | $3,120.00 |
DisclosureSEC source: 0001420506-21-000010 · doc4_894.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,251 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 18:10 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 547 | $5.71 | $3,123.37 |
DisclosureSEC source: 0001420506-20-001037 · doc4_857.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,043 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 13:31 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 879 | $3.55 | $3,120.45 |
DisclosureSEC source: 0001171520-20-000285 · doc4_814.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,496 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020. Read SEC document |
| June 03, 2020 Filed Jun 17, 2020 16:14 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001420506-20-000695 · doc4_808.xml · derivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 875 | $3.57 | $3,123.75 |
DisclosureSEC source: 0001420506-20-000351 · doc4_793.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,617 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2020. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 630 | $4.96 | $3,124.80 |
DisclosureSEC source: 0001420506-20-000010 · doc4_783.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,742 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 16:08 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 607 | $5.15 | $3,126.05 |
DisclosureSEC source: 0001534424-19-000271 · ownership.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,112 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 16:09 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 987 | $3.17 | $3,128.79 |
DisclosureSEC source: 0001534424-19-000198 · ownership.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,505 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.17 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 28, 2019. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 16:09 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001534424-19-000175 · ownership.xml · derivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2020 annual meeting of stockholders. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 16:09 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 993 | $3.15 | $3,127.95 |
DisclosureSEC source: 0001534424-19-000100 · ownership.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,518 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.15 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2019. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 17:08 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,125 | $1.47 | $3,123.75 |
DisclosureSEC source: 0001534424-19-000010 · ownership.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,525 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2018. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 16:41 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,778 | $1.76 | $3,129.28 |
DisclosureSEC source: 0001534424-18-000337 · ownership.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,400 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $1.76 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 28, 2018. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 16:08 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,434 | $2.18 | $3,126.12 |
DisclosureSEC source: 0001534424-18-000240 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,622 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.18 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 29, 2018. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 08:50 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001534424-18-000208 · jenkins.xml · derivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2019 annual meeting of stockholders. Read SEC document |
| March 30, 2018 Filed Apr 2, 2018 16:55 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 997 | $3.13 | $3,120.61 |
DisclosureSEC source: 0001534424-18-000112 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,188 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.13 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 29, 2018. Read SEC document |
| December 29, 2017 Filed Jan 26, 2018 16:09 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,273 | $2.75 | $3,500.75 |
DisclosureSEC source: 0001534424-18-000030 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,191 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.75 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 29, 2017. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:21 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001534424-17-000500 · jenkins.xml · derivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-12 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2018 annual meeting of stockholders. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 16:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001534424-17-000413 · jenkins.xml · derivative · entry 2 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-10-04 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the first anniversary of the grant date, October 4, 2018. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 16:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,280 | $2.47 | $3,161.60 |
DisclosureSEC source: 0001534424-17-000413 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,918 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $2.47 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 29, 2017. Read SEC document |
| May 26, 2017 Filed May 30, 2017 16:24 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | PurchaseWarrants (right to buy) · Derivative | 7,500 | Not disclosed Strike: $2.20 | Not disclosed |
DisclosureSEC source: 0001534424-17-000241 · jenkins.xml · derivative · entry 2 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2022-05-26 F1 · price: The reported securities are included within 7,500 units purchased by the Reporting Person for $2.00 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. F2 · derivative.exercise_date: The shares subject to this warrant are immediately exercisable. Read SEC document |
| May 26, 2017 Filed May 30, 2017 16:24 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | PurchaseCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001534424-17-000241 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,638 F1 · price: The reported securities are included within 7,500 units purchased by the Reporting Person for $2.00 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 16:55 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 701 | $2.64 | $1,850.64 |
DisclosureSEC source: 0001534424-17-000014 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,138 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $2.64 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 30, 2016. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:38 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 425 | $6.65 | $2,826.25 |
DisclosureSEC source: 0001534424-16-001074 · jenkins.xml · nonDerivative · entry 1 Jenkins Kimble L. · CIK 0001492392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,437 F1 · price: These shares were issued pursuant to the issuer's Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under such plan. The shares were issued at a price of $6.65 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2016. F2 · balance_after: This amount corrects a typographical error, which inadvertently overstated the reporting person's holdings, in the previously filed Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.